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Background: Leukotriene receptor antagonists have been studied in the management of moderate to 
severe stable COPD with controversial results. However, there is very little information on their use in 
acute exacerbations of COPD.  
The aim of this study is to find whether Leukotriene receptor antagonists may accelerate the lung 
function recovery & shorten the period of hospital stay when given in acute exacerbation of COPD. 
Patients & Methods: 54 patients were included in this study; their mean age was 59 years (SD +/− 
7.50). The majority were males (72%). 
The trial was conducted at the Merjan teaching Hospital to assess the efficacy of oral montelukast on 
patients who were admitted to the hospital with acute exacerbation of COPD. The study group was 
randomly divided into group I (30 patients) which were given montelukast along with standard therapy 
throughout the hospital stay & group II (24 patients) which were given standard therapy alone. 
Improvements in lung function and duration of hospital stay were monitored. 
Results: There was better improvement in pulmonary function test results at discharge & on follow up 
7 days post discharge & less duration of hospital stay  in group I patients compared to group II. No 
serious adverse effects were noted during the course of the study. 
Conclusion: Our study suggests that there is a benefit of addition of oral montelukast over 
conventional treatment in the management of acute exacerbation of COPD. 
Keywords: montelukast . spirometry . Hospital length of stay . Acute exacerbation . Chronic 
obstructive pulmonary disease  
 ةصلاخلا 
 ىلع ةيلاحلا ةساردلا تيرجا45  ىفشتسم يف ةماعلا ةهدرلا ىلا اولخدا نمزملا تابصقلا باهتللا داح جيهتب باصم ضيرم
 راذا نم ةرتفلل ناجرم2102  راذا ةياغلو2105  هذه جلاعل مدختسملا يجذومنلا جلاعلل تساكوليتنوملا راقع ةفاضا ريثات ةفرعمل
ا فئاظو جئاتن ىلع تلاحلا ىلولاا ةعومجملا ,نيتعومجم ىلا ىضرملا ميسقت مت ثيح .ىفشتسملا يف مهدوقر ةرتف ىلعو ىضرملل ةئرل
(01 ( ةيناثلا ةعومجملاو يجذومنلا جلاعلل ةفاضا تساكوليتنوملا راقع مهئاطعا مت ) ضيرم25  يجذومنلا جلاعلا مهئاطعا مت )ضيرم
ملل مهلوخد دنع ىضرملل ةئرلا فئاظو سايق مت .طقف ةساردلا جئاتن نمو .جورخلا دعب مايا ةعبس مهتعجارم دنع و جورخلا دنعو ىفشتس
 لدي امم ةيناثلا ةعومجملا ىضرمب ةنراقم ىفشتسملا يف لقا ءاقب ةرتفو ىلولاا ةعومجملا ىضرمل ةئرلا فئاظو يف نسحت ظحول ةيلاحلا
يجذومنلا جلاعلل تساكوليتنوملا جلاع ةفاضلا ةدئاف دوجو ىلع 
 تاملكةيحاتفم ةيجيهت تابون , نمزملا تابصقلا باهتلا ,رتيموريابسلا ,تساكوليتنوم :  
Introduction  
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable 
disease; its pulmonary component is characterized by airflow limitation that is not 
fully reversible, usually progressive and associated with an abnormal inflammatory 
response of the lungs to noxious particles or gases (GOLD, Executive summary 2006). 
Acute exacerbation of COPD is defined as an acute increase in dyspnea, sputum 
volume, and/or sputum purulence without other attributable cause 
COPD exacerbations were responsible for 726,000 hospitalizations and 119,000 
deaths in the United States (Mannino et al., 2002).  
The usual management of acute exacerbations of COPD has not changed in the 
last 30 years & consists of bronchodilators, corticosteroids, and antibiotics; the only 
exception is the use of noninvasive ventilation. 
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Leukotrienes are inflammatory mediators that are derived from arachidonic acid, 
initially through 5-lipoxygenase enzymatic activity. Subsequent enzymatic steps 
generate either LTB4, which mediates neutrophil and T-cell chemotaxis, or the 
cysteinyl leukotrienes (LTC4, LTD4, LTE4), which cause smooth muscle contraction, 
tissue edema, inflammatory cell chemotaxis, and mucus production (Peters-Golden, 
2008).  
The reasons for our study of montelukast in Acute exacerbation of COPD was 
because many studies show the role of both of the above classes of leukotrienes in the 
pathophysiology of Acute exacerbation of COPD (Crooks et al., 2000; Biernacki 
 et al., 2003; Shindo et al., 1997; Hill et al., 1999; Nannini et al., 2003), and another 2 
clinical studies, which have found increased serum and exhaled breath leukotrienes 
levels in patients with COPD despite corticosteroid use (Seggev et al., 1991; 
Montuschi  et al., 2003) (indicating that any benefit of leukotrienes blockade might be 
additive to those of corticosteroids). 
Clinical trials of anti-leukotriene therapy in COPD (Despite the above data) have 
focused only on patients with chronic stable disease (Gompertz et al., 2002; Celik et 
al., 2005). To date, there are only few published randomized trials of anti-leukotriene 
therapy in acute exacerbation of COPD. However, a prior randomized controlled trial 
demonstrated rapid improvements in FEV1 and a reduction in treatment failure with 
the use of leukotriene receptor blockade for the treatment of asthma exacerbations in 
the emergency department (Camargo et al., 2003). 
Based on studies of mediators of inflammation in COPD, clinical trials of anti-
leukotriene therapy in stable COPD, and a clinical trial of anti-leukotriene therapy in 
exacerbations of asthma, we hypothesized that anti-leukotriene therapy would provide 
a novel therapeutic approach to Acute exacerbation of COPD requiring 
hospitalization. Our primary goal was to reduce hospital length of stay.  
Montelukast is the most commonly used cysteinyl leukotrienes receptor 1 
(CysLT-1) antagonist. It has been shown to improve symptoms and lung function 
(FEV1) within 15 minutes of administration in chronic asthma with its effects lasting 
for a period of at least 24 hours [Dockhorn RJ et al., 2000]. 
 
Patients and method  
The study was conducted over a period of two years from March 2012 to March 
2014. All patients presenting either to the emergency department or outpatient clinics 
of Merjan teaching hospital requiring hospitalization with acute exacerbation of 
COPD were screened for inclusion in the study.  
Fifty four patients were included in this study; their mean age was 59 years (SD +/− 
7.5). The majority were males (72%). 
The study group was randomly divided into two groups  
*** Group I (30 patients) which were given oral montelukast sodium (10 mg once 
daily)  along with standard therapy throughout the hospital stay  
*** Group II (24 patients) which were given standard therapy alone.  
The standard therapy included nebulized salbutamol, a 14-day course of systemic 
corticosteroids beginning with at least 40 mg of prednisone (or its equivalent) per day 
and a course of an antibiotic selected on the basis of local resistance patterns to S. 
pneumonia, H. influenza, and M. catarrhalis. 
The inclusion criteria included a diagnosis of acute exacerbation COPD (defined 
as an acute increase in dyspnea, sputum volume, and/or sputum purulence without 
other attributable cause). Other inclusion criteria were ≥10 pack-years smoking 
history and an FEV1 <60% predicted at time of inclusion or an inability to perform 
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spirometry due to dyspnea.The patients with the following conditions were excluded 
from the study; patients with FEV1 > 70% predicted or PEF > 300 L/min, 
concomitant therapy with systemic corticosteroids or leukotriene modifiers at any 
time in the past 4 weeks at the time of admission, any concurrent acute medical 
condition like myocardial infarction, congestive cardiac failure, diabetic ketoacidosis 
or shock, acute respiratory failure requiring mechanical ventilation, and improvement 
in symptoms after being included into the study leading to discharge from the 
emergency department. Patients who were unwilling to be enrolled in the study were 
also excluded.  
The patients underwent a baseline spirometry testing soon after enrollment. 
A brief questionnaire was used to obtain information about the duration, severity 
and treatment of COPD. 
The spirometry was done using MIR spirolab III. The spirometry test was 
repeated three times. Each test was performed within three minutes of the previous 
one. The spirometry was done on admission and discharge & on follow up 7 days post 
discharge.  
The primary outcomes of the study were  
a) Improvement in lung function measured as FEV1, FVC & FEV1/FVC ratio over 
the course of hospital stay, discharge & 7 days post discharge. 
c) Duration of hospital stay. 
 
Results 
The baseline characteristics of both study groups are shown in table 1 
 
Subjects characteristics  Group 1 (30 
patients ) 
Group 2 (24 
patients ) 
p- value 
Age 62 ± 6 61± 9 0.24 
Men 22 17 0.36 
Current smoking 44 % 41 % 0.45 
Spo2 (without o2) on 
admission 
87 % 88 % 0.56  
Baseline FEV1 (L) 0.79 ± 0.49 0.85 ± 0.30 0.30 
FEV1 % predicted 32 ± 11 32 ± 12 0.86 
Baseline FEV1/FVC (%) 44 ± 12 40 ± 10 0.41 
 
Data are presented as mean ± SD or percentage, BD denotes bronchodilator. 
There were no significant differences in the baseline characteristic between the two 
study groups. 
*** There was a significant difference in the pulmonary function test results between 
both study groups at discharge from the hospital and 7 days post discharge.  
The spirometric results at discharge from the hospital are shown in table 2  
Spirometric results  Group 1 ( 30 ) Group 2 ( 24 ) P – value  
FEV1 (L) 1.17 ± 0.54 0.93 ± 0.26 0.001  
FEV1 (% predicted) 40 ± 9 36 ± 13 0.001 
FVC 2.61 ± 0.78    2.23 ± 0.98 0.001 
FEV1/FVC 44 ± 7 41 ± 3 0.2 
 
Data are presented as mean ± SD or percentage 
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***The patients who received montelukast ( group 1 ) had a mean FEV1 of 1.17 ± 
0.54 L/min while those on conventional treatment ( group 2 ) had a mean FEV1 of 
0.93 ± 0.26 L/min on discharge (p = 0.001). Similar trend was seen in the FVC, where 
the mean values for group 1 and group 2 patients were 2.61 ± 0.78 L/min and 2.23 ± 
0.98 L/min respectively (p = 0.001) (Table 2 & figure 1). 
The spirometric results at 7 days from discharge from the hospital are shown in table 
3 
 
Spirometric results  Group 1 ( 30 ) Group 2 ( 24 ) P – value  
FEV1 (L) 1.29± 0.86 0.97 ± 0.35 0.001  
FEV1 (% predicted) 42 ± 1 37 ± 23 0.001 
FVC 2.83 ± 0.72    2.42 ± 0.62 0.001 
FEV1/FVC 46 ± 12 42 ± 6 0.001 
 
The most remarkable differences in pulmonary function test results were noted at 
7 days from discharge from hospital were the mean FEVI  group 1 patients was 1.29± 
0.86 L/ min whereas in group 2 patients was 0.97 ± 0.35 L/ min (p = 0.001). Similar 
results were noted in FVC values it was in group 1 patients 2.83 ± 0.72 L/ min & in 
group 2 patients 2.42 ± 0.62 L/ min (p = 0.001). 
The study also shows a significant difference in the length of hospital stay where 
it was lower in group 1 patients 3.84 ± 2.61 days & higher in group 2 patients 4.84 ± 













Figure 1 the results of FEV1 & FVC in both study groups are expressed as L/min 




Many laboratory and clinical studies suggest an important role for leukotrienes 
in the pathogenesis of inflammation in stable COPD. Expression of two LTB4 
receptors, BLT1 and PPARα, is increased in alveolar macrophages and airway wall 
leukocytes in surgical lung specimens from patients with COPD (Marian E et al., 
2006). LTB4 levels are elevated in exhaled breath condensate (10, Kostikas K et al., 
2005), sputum (Kostikas K et al., 2005) and serum (Seggev JS et al., 1991) in patients 
with stable COPD as are plasma levels of the cysteinyl leukotriene, LTC4 (Nannini LJ 
Jr et al., 2003). To date, 2 clinical trials of anti-leukotriene therapy in stable COPD 
have been published (Gompertz S et al., 2002 ; Celik P et al., 2005). 
The first study is compared daily therapy with montelukast to placebo in 117 
patients over 2 months (Celik P et al., 2005). Significant improvements in FVC, 
FEV1, PaO2 and St. George’s Respiratory Questionnaire (SGRQ) scores (p < 0.05) 
were observed in the montelukast group with no comparable improvements in the 
placebo group. 
The second was a trial of the effect of an oral leukotriene synthesis inhibitor 
BAYx1005 (500 mg twice daily) on sputum biomarkers (Gompertz S et al., 2002). 
Sputum LTB4 levels were reduced, but no differences were observed in sputum 
myeloperoxidase concentration or neutrophil chemotaxis between the 2 treatment 
arms. 
Few studies also support a possible role for leukotrienes in acute exacerbation 
of COPD. Two prior studies showed that blood LTE4 levels were elevated in acute 
exacerbations and that levels decreased with treatment (Shindo K et al., 1997 ; Pinto-
Plata VM et al., 2007). Similarly, sputum and exhaled breath condensate LTB4 levels 
are elevated in acute exacerbation of COPD and decline with treatment (Biernacki 
WA et al., 2003; Shindo K et al., 1997 ; Hill AT et al., 1999). In an accompanying in 
vitro study, Crooks and colleagues (Crooks SW et al., 2000) showed that LTB4 
contributed approximately 30% of total neutrophil chemotactic activity in the sputum 
of these subjects during acute exacerbations. 
Our study shows that the use of montelukast, when added to usual treatment of 
acute exacerbation of COPD, resulted in improvement of clinical features (manifested 
by improving breathlessness ), more rapid improvement in pulmonary function test 
results & shorter duration of hospital stay compared to the other study group, 
Supporting the results of the above studies which show clear evidence of effects of the 
leukotriene inhibitor on leukotriene levels in patients with COPD.  
The patients who were included in this study had relatively severe COPD before 
the start of the study which might have influenced the likelihood that leukotriene 
antagonism would be beneficial during an exacerbation. Approximately 37 % of our 
patients were using home oxygen therapy before hospital admission, and 68 % have 
history of a hospital visit for COPD in the last year. The spirometric data available 
before the current study (before this admission) suggest that more than half of the 
subjects had GOLD stage III and IV disease. Therefore, studying patients admitted to 
the hospital with acute exacerbation of COPD with relatively severe COPD at 
baseline, could limit the absolute benefit of interventions made during exacerbations 
through leukotriene antagonism & only results in mild but statistically significant 
clinical & spirometric benefit.  
In summary, the important findings of this study were that we found clinically& 
statistically significant effect of montelukast on hospital length of stay & pulmonary 
function test results through leukotriene antagonism which according to the results of 
the above study reduces cysteinyl leukotriene levels in hospitalized patients with 
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acute exacerbation of COPD. Whether this pharmacologic effect leads to 
improvements in all patients with acute exacerbation of COPD is uncertain because of 
the limited number of patients included in this study. Finally, the use of montelukast 
in patients with acute exacerbation of COPD has no significant adverse effects noted 
during the study period.  
These safety data, obtained in relatively sick patients with acute exacerbations 
of lung disease, may encourage the development of further clinical trials of this 
therapy in stable COPD or in other inflammatory diseases. 
 
Recommendation  
The results of this study should encourage the design of another prospective 
study with larger sample size to assess the effect of montelukast on the clinical 
outcome in patients with acute exacerbation of COPD because even modest 
improvement will reduce the high cost and health impact of those acute exacerbations 
which require hospitalizations. 
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